ArticleLipids in health and disease2025
Maternal dyslipidemia in the first trimester and adverse pregnancy and offspring outcomes: based on the Tianjin birth cohort.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundLimited studies demonstrated the relationships between first-trimester maternal dyslipidemia and adverse pregnancy-offspring complications. This investigation aimed to probe (1) the relationships of first-trimester maternal dyslipidemia with adverse pregnancy and birth outcomes, and (2) the potential influence of first-trimester maternal lipid profiles on offspring growth trajectories.
methodsA prospective observational investigation was conducted within the structure of the Tianjin Birth Cohort, in which maternal blood samples were acquired (median at 11th gestational week) to measure lipid levels. Group-based trajectory modeling was employed to classify latent offspring growth trajectories. Poisson regression incorporating robust standard error was employed to analyze the associations of maternal dyslipidemia with adverse pregnancy-offspring complications.
resultsFirst-trimester maternal dyslipidemia significantly increased gestational diabetes mellitus risk after adjustment for confounders (relative risk: 1.36, 1.20–1.54), but did not link to gestational hypertension (1.13, 0.89–1.43) risk. In addition, first-trimester maternal dyslipidemia elevated preterm birth (1.24, 1.03–1.49) and large for gestational age (1.27, 1.12–1.43) risks. However, first-trimester maternal dyslipidemia showed no significant link with either small for gestational age risk (0.83, 0.67–1.03) or offspring growth trajectories from birth to 24 months (lower growth trajectory: 0.99, 0.93–1.06; higher growth trajectory: 0.97, 0.88–1.08).
conclusionsFirst-trimester maternal dyslipidemia elevated adverse pregnancy and offspring status risks, specifically maternal gestational diabetes mellitus, as well as offspring preterm birth, and large for gestational age, but did not link to maternal gestational hypertension, small for gestational age, or variations in offspring growth trajectories from birth to 24 months.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.